Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis.

[1]  H. Schunkert,et al.  Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study) , 2019, European heart journal.

[2]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[3]  J. Brachmann,et al.  Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  L. Satler,et al.  In-Stent Restenosis of Drug-Eluting Stents Compared With a Matched Group of Patients With De Novo Coronary Artery Stenosis. , 2018, The American journal of cardiology.

[5]  Seung‐Jung Park,et al.  Comparison of drug‐eluting stents and drug‐coated balloon for the treatment of drug‐eluting coronary stent restenosis: A randomized RESTORE trial , 2018, American heart journal.

[6]  Andreas Bender,et al.  A generalized additive model approach to time-to-event analysis , 2018 .

[7]  M. Beijk,et al.  A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial. , 2017, JACC. Cardiovascular interventions.

[8]  B. García del Blanco,et al.  Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials). , 2017, The American journal of cardiology.

[9]  A. Kirtane,et al.  Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents , 2017, The International Journal of Cardiovascular Imaging.

[10]  B. García del Blanco,et al.  Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials , 2016, Circulation. Cardiovascular interventions.

[11]  O. Hlinomaz,et al.  Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study , 2016, Circulation. Cardiovascular interventions.

[12]  Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients , 2015, BMJ : British Medical Journal.

[13]  Michael Joner,et al.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 , 2015, European heart journal.

[14]  R. Virmani,et al.  Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. , 2015, European heart journal.

[15]  K. Kadota,et al.  Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. , 2015, Journal of the American College of Cardiology.

[16]  A. Íñiguez,et al.  A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.

[17]  H. Schunkert,et al.  Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. , 2015, European heart journal.

[18]  W. Desmet,et al.  Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[19]  Fernando Alfonso,et al.  Current treatment of in-stent restenosis. , 2014, Journal of the American College of Cardiology.

[20]  A. Íñiguez,et al.  A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). , 2014, Journal of the American College of Cardiology.

[21]  Shao-Liang Chen,et al.  A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. , 2014, JACC. Cardiovascular interventions.

[22]  M. Joner,et al.  Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[23]  R. Virmani,et al.  Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. , 2013, European heart journal.

[24]  Jeffrey E. Jarrett.  Book Reviews , 2013 .

[25]  Y. Hayashi,et al.  A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. , 2013, American heart journal.

[26]  P. Serruys,et al.  Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. , 2013, JACC. Cardiovascular interventions.

[27]  A. Kastrati,et al.  Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial , 2013, The Lancet.

[28]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[29]  Soo-Jin Kang,et al.  In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.

[30]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[31]  L. Hedges,et al.  Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.

[32]  G. Lemesle,et al.  Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. , 2009, The American journal of cardiology.

[33]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[34]  D. Simon,et al.  Molecular Basis of Restenosis and Drug-Eluting Stents , 2005, Circulation.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[37]  L. Stewart,et al.  Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. , 2015, JAMA.

[38]  F. Eberli,et al.  revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial , 2022 .